PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
Sara Rockwell, PharmaMar usa, Inc., Preliminary Studies of the Effects of Aplidine in Hypoxic Environments and in Combination with Radiation, 1 year, $67,035